# PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma

> **NCT07641010** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 112 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** PD-1+JAK1i
- **DRUG:** PD-1

## Key facts

- **NCT ID:** NCT07641010
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07641010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07641010, "PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07641010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*